Table 2 Costs and reimbursement for nosocomial VRE and VSE infections
From: Economic burden of nosocomial infections caused by vancomycin-resistant enterococci
|  | VRE infection (n = 42) | VSE infection (n = 42) | p-valuea |
|---|---|---|---|
Costs per patient (EUR) | 57,675 (34,253 to 124,079) | 38,344 (20,872 to 76,353) | 0.030 |
Costs per patient before the onset of the infection (EUR) | 17,893 (10,664 to 32,191) | 16,600 (7373 to 24,723) | 0.386 |
Costs per patient after the onset of the infection (EUR) | 37,971 (17,786 to 80,662) | 23,025 (10,322 to 40,565) | 0.049 |
Reimbursement per patient (EUR) | 40,084 (20,128 to 99,501) | 26,116 (10,898 to 57,139) | 0.032 |
Loss per patient (EUR) | 14,003 (1974 to 32,743) | 6883 (3123 to 20,511) | 0.227 |
Median costs attributable to vancomycin-resistance in enterococci infection per patient (EUR)b | 13,157(−16,420 to 74,593) | 0.036 | |